The American Nurses Association has named a vice president of AI and Digital Health Programs to lead a three-year initiative backed by Johnson & Johnson Foundation and Google.org funding.
GSK expanded its Chai Discovery AI drug-design partnership only after its own scientists validated the results, reflecting pharma's cautious AI embrace.
Tempus AI is pushing ahead with a roughly $1.5 billion all-stock acquisition of genomic testing company Personalis, a bet on expanding its precision oncology platform that sent both companies' shares lower when it was announced.
Pfizer has licensed Chai Discovery's AI protein design platform for its drug pipeline, as the startup diversifies beyond its existing Eli Lilly partnership following a $400 million funding round.
AI drug discovery licensing deals hit $47.1 billion in the first half of 2026, already surpassing all of 2025, even as no AI-discovered drug has yet won full FDA approval.
Takeda signed a $600 million AI drug discovery deal with Insilico Medicine, joining Eli Lilly and AstraZeneca in a wave of major pharma bets on AI-driven drug development in 2026.
AstraZeneca and Oracle announced a global AI collaboration on October 20, 2026 to speed clinical trial recruitment and early diagnosis, starting with a hypertension pilot in Abu Dhabi built on deidentified real-world data.
A new AI system called Cytoreader-Fusion automated dual-stain cervical cancer screening reads across more than 9,000 slides in a retrospective study, part of a broader wave of AI cancer-screening research in 2026.
Major medical societies pushed back on growing AI autonomy in clinical care, arguing diagnostic AI remains a valuable tool but physician judgment must stay central, especially for cases falling outside a model's training patterns.
Gabit raised roughly $4.3 million to expand its AI-powered preventive healthcare platform in India, part of a broader funding wave into wearable startups built around proprietary health data.